Delivery Order SPE2DB20D1047-SPE2DB25FF74R
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,138.73 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 31, 2025, and represents a child contract under AmerisourceBergen's broader pharmaceutical supply agreements with DLA. The products will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,833.48 to AmerisourceBergen Drug Corp for OmniPod 5 DexG7G6 pods (Generation 5) in 5-count packages. This firm fixed-price, non-set-aside contract was awarded on August 11, 2025, with an ultimate completion date of August 12, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The OmniPod 5 is an insulin delivery system widely used for diabetes management, and...
- The Defense Logistics Agency awarded a $2,395.34 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed price procurement with no set-aside designation. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this medical device delivery, which supports the federal government's...
- The Defense Logistics Agency awarded a delivery order valued at $28,082.40 to AmerisourceBergen Drug Corp for OmniPod 5 DexG7G6 Pods (Generation 5), 5-unit packages. This competitively awarded, firm fixed-price delivery order, issued on September 19, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The products will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $7,762.89 to AmerisourceBergen Drug Corp for OmniPod 5 DEXG7G6 Pods (Generation 5) with a 5-second functionality. This competitively awarded, firm fixed-price delivery order was issued on September 18, 2025, with an ultimate completion date of September 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,876.41 to AmerisourceBergen Drug Corp for the OMNIPOD 5 DEXG7G6 INTRO (GEN 5)S on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a product delivery to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $6,549.99 to AmerisourceBergen Drug Corp on September 8, 2025, for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. The contract is a firm fixed price delivery order with an ultimate completion date of September 9, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition without a set-aside designation, reflecting AmerisourceBergen's established...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,715.24 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 insulin infusion pump pods (Generation 5) with a completion date of August 28, 2025. This non-competed delivery order utilizes firm fixed pricing and will be performed at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, is positioned as a critical vendor...
- The Defense Logistics Agency awarded a delivery order valued at $36,377.71 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 generation 5 insulin infusion pump pods. This firm fixed-price delivery order was competitively awarded without a set-aside designation and carries an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,784.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 DEXG7 Gen 5 insulin infusion pods. The contract, issued on September 2, 2025, with an ultimate completion date of September 3, 2025, represents a competitive award with no set-aside designation. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- SPE2DB20D1047Indefinite Delivery Contract
- SPE2DB20D1047-SPE2DB25FF74RDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $14,277.78 to AmerisourceBergen Drug Corp for OMNIPOD 5 DEXG7G6 Pods (Generation 5) 5-unit supplies. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 29, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was awarded through open competition based on merit and capability. This delivery order is a child contract under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical devices to military healthcare systems and other federal agencies. The OMNIPOD 5 insulin delivery system represents the company's specialized medical device offerings within its broader portfolio of diabetes management and therapeutic solutions serving Department of Defense and other federal health programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.3k | 7/28/25 |